Paclitaxel Delivery to the Brain for Glioblastoma Treatment

Muhammad AbdEl-haq, Awanish Kumar, Fatima Ezzahra Ait Mohand, Nataly Kravchenko-Balasha, Yakir Rottenberg, Abraham J. Domb

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The development of paclitaxel-loaded polymeric nanoparticles for the treatment of brain tumors was investigated. Poly(lactide-glycolide) (PLGA) nanoparticles containing 10% w/w paclitaxel with a particle size of 216 nm were administered through intranasal and intravenous routes to male Sprague–Dawley rats at a dose of 5 mg/kg. Both routes of administration showed appreciable accumulation of paclitaxel in brain tissue, liver, and kidney without any sign of toxicity. The anti-proliferative effect of the nanoparticles on glioblastoma tumor cells was comparable to that of free paclitaxel.

Original languageEnglish
Article number11722
JournalInternational Journal of Molecular Sciences
Volume24
Issue number14
DOIs
StatePublished - 21 Jul 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 by the authors.

Funding

This study was supported in part by the Israel Cancer Research Fund (ICRF) and Israel Cancer Association Grant (2019).

FundersFunder number
Israel Cancer Research Fund
Israel Cancer Association

    Keywords

    • brain delivery
    • glioblastoma treatment
    • intranasal (IN)
    • intravenous (IV)
    • nanoparticles (NPs)
    • paclitaxel (PTX)
    • poly(lactic-co-glycolic acid) (PLGA)

    Fingerprint

    Dive into the research topics of 'Paclitaxel Delivery to the Brain for Glioblastoma Treatment'. Together they form a unique fingerprint.

    Cite this